top of page

Pleryon Therapeutics Announces Global Exclusive License Agreement for a Novel
Therapeutic Polymer for the Treatment of Osteoarthritis

2022年11月8日

Pleryon Therapeutics is pleased to announce that it has entered into a licensing agreement with Cornell University to obtain an exclusive global license for a new class of therapeutic polymer and its patented technology. Under this agreement, Pleryon will have the exclusive rights to develop this technology globally for the treatment of osteoarthritis (OA) and other indications.


OA is a chronic joint disease characterized by the progressive degeneration of articular cartilage. It is estimated that closed to 600 million people worldwide suffer from OA. With an aging population and changes in modern lifestyles, the prevalence of OA is increasing and occurring earlier in life.


Despite significant efforts in the past decades, an effective treatment for OA is still lacking. Many patients struggle with the disease, facing a severe reduction in quality of life and a high economic burden, highlighting the urgent need for new treatments for osteoarthritis.


Yu Yu, founder and CEO of Pleryon, stated, “Pleryon is dedicated to developing innovative products using polymer technologies. Osteoarthritis (OA) represents a significant area of unmet medical need, and we believe that the polymer-based technology licensed from Cornell University can bring substantial value to OA patients worldwide. I am confident that Pleryon will swiftly commercialize this technology and launch products with significant clinical value in the near future."

bottom of page